Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, College of Medicine, Yonsei University, Seoul, Korea.
Pancreatobiliary Cancer Center, Yonsei Cancer Center, Severance Hospital, Seoul, Korea.
Cancer Biomark. 2019;24(3):335-342. doi: 10.3233/CBM-181847.
For patients with pancreatic cancer, a preoperative assessment of prognosis is crucial to predict cancer recurrence and to prepare a postoperative adjuvant strategy and appropriate patient-counsel.
We evaluated the prognostic predictive power of complement factor B (CFB) by comparing it to that of other known tumor markers in resected pancreatic cancer patients.
From 2012 to 2013 period, we retrospectively reviewed the plasma CFB levels of 35 pancreatic cancer patients. The patients were divided into two groups according to serologic CFB values. Disease-free survival (DFS) and overall survival (OS) rates were analyzed.
Based on the cut-off values of plasma CFB, 15 patients were placed in the low CFB group and the other 20 patients were placed in the high CFB group. There was a significant difference in DFS between the two groups (Low CFB vs. High CFB: 36.9 months vs. 13.9 months, p: 0.007). In the OS analysis, there was also a significant difference in the survival rates of the two groups (Low CFB vs. High CFB: 49.7 months vs. 29.0 months, p: 0.048).
Preoperative plasma CFB can be used to predict the prognosis of resectable pancreatic cancers; it outperforms both CA 19-9 and CEA.
对于胰腺癌患者，术前评估预后对于预测癌症复发、制定术后辅助治疗策略和为患者提供适当的咨询至关重要。
我们通过比较补体因子 B（CFB）与其他已知的胰腺癌肿瘤标志物，评估其在可切除胰腺癌患者中的预后预测能力。
回顾性分析 2012 年至 2013 年期间 35 例胰腺癌患者的血浆 CFB 水平。根据血清 CFB 值将患者分为两组。分析无病生存期（DFS）和总生存期（OS）。
根据血浆 CFB 的截断值，将 15 例患者分为低 CFB 组，20 例患者分为高 CFB 组。两组 DFS 差异有统计学意义（低 CFB 组与高 CFB 组：36.9 个月与 13.9 个月，p=0.007）。在 OS 分析中，两组生存率也存在显著差异（低 CFB 组与高 CFB 组：49.7 个月与 29.0 个月，p=0.048）。
术前血浆 CFB 可用于预测可切除胰腺癌的预后，其预测能力优于 CA 19-9 和 CEA。
